Neoprobe to Present at BIO CEO Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Tuesday, February 12, 2008 at 2:45 PM EST, during the 10^th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York, NY.

Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical development program for Lymphoseek, Neoprobe’s lead drug product.

Interested parties can access a live, or archived, internet broadcast of the presentation at:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NEOP&item _id=1762136 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).

The presentation will be archived for 30 days.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000^® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix^® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan^® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.www.neoprobe.com.